Joshua Fitch, Senior Editor

From the FDA approvals of dupilumab and maralixibat tablets to a new puzzler case study, get caught up with our weekly review article.

The CRL issued by the FDA to Regeneron for extended EYLEA HD dosing to 24 weeks cited no safety or efficacy concerns.

The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU.

Recommendations from the ACIP are forwarded to the director of the CDC, and if adopted, become official CDC policy.

Diazepam nasal spray (Valtoco) is approved for short-term treatment of seizure clusters, now in patients aged 2 years and older.

Recent research detailed that a child was most likely to be killed in a mass shooting by a parent or family member vs a stranger or peer. Study investigator Stephanie Chao, MD, breaks down these data.

In the immediate skin-to-skin contact group, improved breastfeeding practices up to 12 months were observed.

Breastfeeding for 6 months was linked to fewer developmental delays and neurodevelopmental conditions, supporting current recommendations.

Overall, findings revealed that a higher proportion of children with autism had a history of motor milestone delays.

In the United States, maralixibat (Livmarli; Mirum Pharmaceuticals) is approved to treat both ALGS and PFIC, now in liquid and tablet formulations.

Infants born moderately preterm had lower composite cognitive scores compared to those born at full-term s (β = −0.39; 95% CI, −0.55 to −0.22; P < .001).

From strong data for JNJ-2113 to a deep dive into climate change and pediatric health care, get caught up with our weekly review article.

Do you know the details from the American Academy of Pediatrics' 2024 CCHD updated screening recommendations?

“Data from the Phase 3 ICONIC LEAD subgroup analysis demonstrate impressive efficacy rates, showing the promise of this novel therapeutic option," said Lawrence Eichenfield, MD.

The federal agency greenlit nivolumab with ipilimumab for treating MSI-H/dMMR colorectal cancer in adults and children 12 years and up.

Ambulatory blood pressure monitoring at point-of-care shows high feasibility for pediatric hypertension diagnosis in clinical practice.

If approved, the expanded indication would include children and adolescents aged 6 to 17 years who weigh 99 lbs (45 kg) or more.

In the phase 3 TRANSCEND trial, setmelanotide met the primary endpoint of a statistically significant and clinically meaningful BMI reduction compared to placebo.

A newly published Swedish study supports other research that suggests screen time displaces sleep in multiple ways.

View our Q1 2025 recap of standout pediatric news from FDA regulatory updates, clinical trial results, and expert commentary.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Fathers who took 2 or more weeks of leave after the birth of their infant were more likely to report longer breastfeeding duration.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from March 2025.

Submission is based on 3 clinical trials, including data from the ApproaCH Trial among children with achondroplasia.

Jay T. Rubinstein, MD, PhD, emphasized that children with hearing loss should receive genetic testing, as the investigational DB-OTO gene therapy demonstrated positive results.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Fitusiran is administered subcutaneously starting once every 2 months for patients aged 12 years and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors.

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.

Mesoblast's remestemcel-L (Ryoncil) was approved by the FDA on December 18, 2024 to treat SR-aGVHD in patients 2 months and older. Now, it is available for purchase.

Peter Lio, MD, offers thoughts on recent atopic dermatitis data reported for lebrikizumab.